Boehringer Ingelheim – Schizophrenia
The study is looking to prevent patients with Schizophrenia from becoming worse or relapsing over a 6 month time period.
Sponsors: Boehringer Ingelheim
Phase : 2
Age: 18 years to 55 years
For more information please visit https://clinicaltrials.gov/ct2/show/NCT03351244
Studies Currently Available At
- Kelowna View Location